NKY(SZ:300109) Shang Hai Zheng Quan Bao·2025-10-27 22:09Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, with all board members assuming legal responsibility for any misrepresentation or omissions [2][3]. Financial Data - The third-quarter financial report has not been audited [3][7]. - There are no adjustments or restatements of previous accounting data [3]. - The company does not have any non-recurring gains or losses [3]. Shareholder Information - The company has reported changes in the number of shareholders and the status of restricted shares [5]. Other Important Matters - A subsidiary has received approval for clinical trials of a new drug for advanced solid tumors [5]. - The company plans to distribute cash dividends amounting to 121,175,001.25 yuan, with a record date of July 9, 2025 [5]. - The company is investing a total of 50 million yuan in Huadao (Shanghai) Biomedicine Co., Ltd. to enhance its competitive advantage in precision medicine [6].